Labcorp, a global leader in innovative and comprehensive laboratory services, has appointed Victor Bulto to its Board of Directors, strengthening the company’s leadership with deep pharmaceutical and healthcare expertise.
Bulto is a highly accomplished global executive with more than 25 years of experience across the healthcare sector. He currently serves as a key member of Novartis’ executive leadership team, where he leads the company’s U.S. business - an operation generating over US$20 billion in annual revenue.
In this role, he oversees four major therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic, managing complex portfolios in one of the world’s most competitive healthcare markets.
Throughout his career at Novartis, Bulto has been recognized for shaping forward-looking strategies and delivering strong commercial performance amid increasing regulatory scrutiny and market complexity.
His leadership spans both the U.S. and Europe, giving him a global perspective on healthcare delivery, market access, and patient engagement. He has consistently driven transformation initiatives that leverage technology, automation, and data to streamline operations, improve efficiency, and build resilient, future-ready business models.
Bulto brings to Labcorp deep expertise at the intersection of pharmaceutical innovation, digital transformation, and consumer-centric healthcare. His ability to anticipate industry shifts and build organizations prepared for long-term change aligns closely with Labcorp’s mission to advance diagnostics, drug development, and patient-centered care. His appointment is expected to further support Labcorp’s strategic growth and innovation agenda as the company continues to evolve in a rapidly changing healthcare landscape.
